What Wegovy Is Used to Treat — and What It Cannot Do

The biggest misconception: Wegovy is not just for people who want to lose a few kilograms

Many people arrive at this page assuming Wegovy sits somewhere between a diet pill and a lifestyle shortcut. It does not. The licensed indication is weight management in adults with clinically significant excess weight, specifically where that weight is affecting health. A BMI at or above 30 qualifies on its own. A BMI between 27 and 29.9 qualifies when paired with a weight-related condition, things like hypertension, dyslipidaemia, obstructive sleep apnoea, prediabetes or type 2 diabetes.

NICE's appraisal of semaglutide for weight management confirms that the NHS recommends it only within specialist weight management services, for a maximum of two years, and only where at least one weight-related comorbidity is present. That is not a bureaucratic hurdle for its own sake, it reflects who the medicine was actually studied in and where the evidence is strongest. The full picture of what Wegovy treats goes further than the number on the scales, which is the point most people miss.

Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, in line with UK guidance on ethnicity-adjusted risk. A prescriber weighs the whole clinical picture, not the BMI figure alone. If you are hoping Wegovy will be approved simply because you dislike how you look, a prescriber will tell you plainly that it is not the right tool for that.

Beyond weight: the cardiovascular indication most people have not heard of

In 2023 and 2024 the evidence base for semaglutide expanded significantly. Wegovy received a UK authorisation to reduce the risk of major cardiovascular events, specifically heart attack and stroke, in adults who already have cardiovascular disease and who meet the weight criteria. This is not a secondary benefit that came out of the weight-loss trials by accident; it was the primary outcome of a dedicated programme. For some patients, the cardiometabolic case for treatment is as strong as the weight-management case.

Then, from 3 July 2026, the MHRA granted a conditional approval for Wegovy in the treatment of MASH, a form of fatty liver disease involving moderate to advanced fibrosis, in adults with obesity. These are still early days for that indication, but it signals that semaglutide's clinical reach continues to widen as trial programmes report. The semaglutide treatment overview covers all three licensed uses in detail.

For people researching Wegovy specifically for weight management, the cardiovascular and liver-disease indications are useful context rather than the main story. What they confirm is that the medicine has been studied rigorously across large populations, and the safety and efficacy data are unusually extensive. Knowing that your prescriber is drawing on that depth of evidence is reassuring.

What Wegovy does not treat, and where people go wrong

Wegovy is not licensed for under-18s. It is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. These are firm lines, not soft suggestions. If any of those situations applies, a prescriber will not approve it, and the right conversation is with your GP or midwife instead.

It is also worth being clear that Ozempic, which contains the same active ingredient, semaglutide, is licensed for type 2 diabetes. Using Ozempic for weight loss is off-label. The MHRA has been explicit that GLP-1 medicines are not assessed or approved for quick or cosmetic weight loss, and sourcing Ozempic without a proper clinical assessment creates real safety risks. The Wegovy weight-loss treatment page explains the distinction properly and is worth a read if you have been seeing Ozempic mentioned as an alternative.

On the diet side, a question our prescribers hear regularly is whether Wegovy works regardless of what you eat. It does not. The licence specifies use alongside a reduced-calorie diet and increased physical activity. Semaglutide reduces appetite, it does not replace nutrition. Adequate protein, fibre and hydration on treatment matter more than most people expect, which is why our guide to eating well on Wegovy is one of the most-visited resources we publish.

How treatment actually works, the mechanism behind the prescription

Semaglutide mimics GLP-1, a hormone released after eating that signals fullness to the brain, slows the rate at which the stomach empties and, in higher doses, reduces appetite between meals. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks among adults without diabetes using semaglutide 2.4mg alongside lifestyle changes. Most weight-related conditions improved alongside that reduction.

The 2.4mg dose is the maintenance target, reached gradually over several months via a dose-escalation schedule set by the prescriber. The titration exists to reduce gastrointestinal side effects, particularly nausea, which are most common in the early weeks. They generally settle. The Wegovy treatment page covers what to expect from each stage.

If you are weighing up whether this fits your situation, the Wegovy overview on our site brings together eligibility, results and access in one place. And if cost is a factor in your thinking, the Wegovy pricing page explains what private treatment typically involves. We're not going to pretend the cost is trivial. What we will say is that a prescription-only medicine is the wrong place to prioritise the cheapest listing over the safest route.

Wegovy is dispensed at nume through our GPhC-registered pharmacy (registration number 9012878, verifiable at the GPhC register), and every consultation is reviewed by a GPhC-registered Independent Prescriber. If you are ready to find out whether it is clinically suitable for you, a free consultation is the place to start.